Galmed Pharmaceuticals Earning Date (GLMD)

USA |NASDAQ |USD |ADR

GLMD Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 3, 2022 Jun 2022 - - $-0.33
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 3, 2022 Jun 2022 - - $0.00

Galmed Pharmaceuticals's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 2022.

GLMD Earnings Date & History Chart

GLMD Earnings & Revenue Forecast

GLMD Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 5 $-1.31 $-1.60 $-1.09

GLMD Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 0 / 0 $-1.31 $-1.31 $-1.30

GLMD Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 4 $0.00 $0.00 $0.00

GLMD Earnings Date & Revenue History

GLMD Earnings History

|
Show More
Show More

GLMD Revenue History

|
Show More
Show More

Galmed Pharmaceuticals Next Earnings Date & Report

GLMD Next Earnings Date & Report Preview: Jun 2022 (FQ)

GLMD's next earnings date is Wednesday, Aug 3, 2022 for the fiscal quarter ending Jun 30, 2022.

Galmed Pharmaceuticals Previous Earnings Dates & Reports

GLMD Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Galmed Pharmaceuticals's previous earnings date was Apr 18, 2022 for its fiscal quarter ended Mar 31, 2022.

GLMD Previous Earnings Date & Report Recap: Dec 2020 (FY)

Galmed Pharmaceuticals's previous annual earnings date was Mar 18, 2021 for its fiscal year ended Dec 31, 2020.

GLMD's earnings per share (EPS) was $-1.35, missing the consensus analysts forecast of $-1.25 by 8.00% , and lower than the previous year's EPS (Dec 2019) by 39.18%.

Revenues were $0.00.

The company reported a net income of $-28.77M.

Galmed Pharmaceuticals reported a free cash flow of $-26.33M for its fiscal year, compared to $-14.95M a year ago.

The company ended the fiscal year with $216.00K in total debt, a decrease of -38.64% compared to the previous year.